Predictors of lowering SBP to assigned targets at 12 months in the Secondary Prevention of Small Subcortical Strokes study

Journal of Hypertension

Volumn 30, Issue 6, 2012, Pages 1233-1240

  Graves, John W ^a   White, Carole L ^b,d   Szychowski, Jeff M ^c   Pergola, Pablo E ^b,d   Benavente, Oscar R ^d   Coffey, Christopher S ^d,e   Hornung, Lindsey N ^c   Hart, Robert G ^b,d  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e UNIVERSITY OF IOWA   (United States)

Author keywords

blood pressure control; hypertension; lacunar stroke; predictors; Secondary Prevention of Small Subcortical Strokes Study; stroke

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIABETIC NEUROPATHY; FEMALE; HEART INFARCTION; HISPANIC; HUMAN; HYPERTENSION; LACUNAR STROKE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK; SYSTOLIC BLOOD PRESSURE;

EID: 84861093846     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328353968d     Document Type: Article

References (37)

1. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265:3255-3264.
2. Kannel WB, Wolf PA, McGee DL, Dawber TR, McNamara P, Castelli WP. Systolic blood pressure, arterial rigidity, and risk of stroke: the Framingham Study. JAMA 1981; 245:1225-1229.
3. Kubo M, Kiyohara Y, Ninomiya T, Tanizaki Y, Yonemoto K, Doi Y, et al. Decreasing incidence of lacunar vs other types of cerebral infarction in a Japanese population. Neurology 2006; 66:1539-1544.
4. Tanizaki Y, Kiyohara Y, Kato I, Iwamoto H, Nakayama K, Shinohara N, et al. Incidence and risk factors for subtypes of cerebral infarction in a general population. The Hisayama Study. Stroke 2000; 31:2616-2622.
5. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, et al. Blood pressure, stroke and coronary heart disease. Part 2, shortterm reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet 1990; 335:827-838.
6. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335:765-774.
7. Chapman N, Huxley R, Anderson C, Bousser MG, Chalmers J, Colman S, et al. Effects of a perindopril-based blood pressure-lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS Trial. Stroke 2004; 35:116-121.
8. Perry HM Jr., Davis BR, Price TR, Applegate WB, Fields WS, Guralnik JM, et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke: the Systolic Hypertension in the Elderly Program (SHEP). JAMA 2000; 284:465-471.
9. Qureshi AI, Suri MFK, Guterman LR, Hopkins LN. Ineffective secondary prevention in survivors of cardiovascular events in the US population: report from the Third National Health and Nutrition Examination Survey. Arch Intern Med 2001; 161:1621-1628.
10. Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, et al. Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). J Clin Hypertens 2002; 4:393-404.
11. Duggirala MK, Cuddihy RM, Cuddihy M-T, Naessens JM, Cha SS, Mandrekar JN, et al. Predictors of blood pressure control in patients with diabetes and hypertension seen in primary care clinics. Am J Hypertens 2005; 18:833-838.
12. Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med 2001; 345:479-486.
13. Julius S, Kjeldsen SE, Brunner H, Hansson L, Platt F, Ekman S, et al. VALUE trial: Long-term blood pressure trends in 13 449 patients with hypertension and high cardiovascular risk. Am J Hypertens 2003; 16:544-548.
14. Kjeldsen SE, Dahlof B, Devereux RB, Julius S, de Faire U, Fyhrquist F, et al. Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: the LIFE study. Am J Hypertens 2000; 13:899-906.
15. Benavente OR, White CL, Pearce L, Pergola P, Roldan A, Benavente MF, et al. The Secondary Prevention of Small Subcortical Strokes (SPS3) study. Int J Stroke 2011; 6:164-175.
16. Pergola PE, White CL, Graves JW, Coffey CS, Tonarelli SB, Hart RG, et al. Reliability and validity of blood pressure measurement in the Secondary Prevention of Small Subcortical Strokes study. Blood Press Monitoring 2007; 12:1-8.
17. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JLJ, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560-2571.
18. Ling J, Ohara Y, Orime Y, Noon GP, Takatani S. Clinical evaluation of the oscillometric blood pressure monitor in adults and children based on the 1992 AAMI SP-10 standards. J Clin Monit 1995; 11:123-130.
19. Spitzer RL, Kroenke K, Williams JB. Validation and utility of a selfreport version of PRIME-MD: the PHQ primary care study. JAMA 1999; 282:1737-1744.
20. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:1004.
21. Egan BM, Zhao Y, Axon RN. US Trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA 2010; 303:2043-2050.
22. Margolis KL, Piller LB, Ford CE, Henriquez MA, Cushman WC, Einhorn PT, et al. Blood pressure control in Hispanics in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension 2007; 50:854-861.
23. Cushman WC, Basile J. Achieving blood pressure goals: why aren't we? J Clin Hypertens 2006; 8:865-872.
24. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363:2022-2031.
25. Weber MA, Julius S, Kjeldsen SE, Brunner HR, Ekman S, Hansson L, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004; 363:2049-2051.
26. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366:895-906.
27. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351:1755-1762.
28. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, et al. A calcium antagonist vs a noncalcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290:2805-2816.
29. Wing LMH, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GLR, et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348:583-592.
30. Wright JT Jr., Agodoa L, Contreras G, Greene T, Douglas JG, Lash J, et al. Successful blood pressure control in the African American Study of Kidney Disease and Hypertension. Arch Intern Med 2002; 162:1636-1643.
31. Oliveria SA, Lapuerta P, McCarthy BD, L'Italien GJ, Berlowitz DR, Asch SM. Physician-related barriers to the effective management of uncontrolled hypertension. Arch Intern Med 2002; 162:413-420.
32. Fagard RH, Van Den Enden M, Leeman M, Warling X. Survey on treatment of hypertension and implementation of World Health Organization/International Society of Hypertension risk stratification in primary care in Belgium. J Hypertens 2002; 20:1297-1302.
33. Godwin M, Birtwhistle R, Seguin R, Lam M, Casson I, Delva D, et al. Effectiveness of a protocol-based strategy for achieving better blood pressure control in general practice. Family Pract 2010; 27:55-61.
34. Corsino L, Yancy WS, Samsa GP, Dolor RJ, Pollak KI, Lin PH, et al. Physician characteristics as predictors of blood pressure control in patients enrolled in the Hypertension Improvement Project (HIP). J Clin Hypertens 2011; 13:106-111.
35. Fung V, Huang J, Brand R, Newhouse JP, Hsu J. Hypertension treatment in a medicare population: adherence and systolic blood pressure control. Clin Therapeut 2007; 29:972-984.
36. Lindholm LH. The problem of uncontrolled hypertension. J Hum Hypertens 2002; 16:S3-S8.
37. Mant J, McManus RJ. Does it matter whether patients take their antihypertensive medication as prescribed? The complex relationship between adherence and blood pressure control. J Hum Hypertens 2006; 20:551-553.